Some pharmacokinetic parameters of salvianolic acid A following single-dose oral administration to rats. (1st January 2018)

• Record Type: Journal Article
• Authors: Sun, Jialin; Song, Junke; Zhang, Wen; Jing, Fanbo; Xu, Wen; Leng, Ping; Quan, Xianghua; Du, Guanhua; Sui, Zhongguo
• Is Part Of: Pharmaceutical biology. Volume 56:Number 1(2018)
• Page Start: 399
• Page End: 406
• Publication Date: 2018-01-01
• Subjects: Absorption -- bioavailability -- transportation -- first-pass metabolism -- elimination; Pharmacognosy -- Periodicals; Materia medica, Vegetable -- Periodicals; 615.321
• DOI: 10.1080/13880209.2018.1491998
• Languages: English
• ISSNs: 1388-0209

Abstract

Abstract: Context: Salvianolic acid A (Sal A) is a hydrophilic bioactive compound isolated from Salvia miltiorrhiza Bunge (Lamiaceae). It exerts beneficial effects after oral administration on diabetic complications. Objective: To systematically study the absorption, distribution and excretion of Sal A after single-dose oral administration. Materials and methods: Animal experiments were conducted in Sprague-Dawley rats. Plasma was sampled at designated times after oral doses of 5, 10 and 20 mg/kg, and an intravenous dose of 50 μg/kg. Tissues were harvested at 10, 60 and 120 min postdosing. Bile, urine and feces were collected at specified intervals before and after dosing. Absorption and distribution characteristics were analyzed by LC–MS, and excretion characteristics were analyzed by UPLC–MS/MS. The Caco-2 cell model was applied to investigate potential mechanisms. Results: The C max (5 mg/kg: 31.53 μg/L; 10 mg/kg: 57.39 μg/L; 20 mg/kg: 111.91 μg/L) of Sal A increased linearly with doses ( r > 0.99). The calculated absolute bioavailability was 0.39–0.52%. Transport experiment showed poor permeability and the ratio of P B–A to P A–B was 3.13–3.97. The highest concentration of Sal A was achieved in stomach followed by small intestine and liver, and it could also be detected in brain homogenate. Approximately 0.775% of its administered dose was excreted via feces, followed by bile (0.00373%) and urine (0.00252%). Discussion and conclusions: These results support the future development of Sal A as an oral drug for the treatment of diabetic complications. Future research should be conducted to investigate the reason for its poor bioavailability and improve this situation.